                         SEQUENCE LISTING

<110>  Aggamin LLC
       Woo S, Joo
       Karen M, Lee
       Adelene Y, Tan
       Garrett D, Daniels
       Paul, Kussie
 
<120>  EX VIVO METHODS AND SYSTEMS USING sENG AND sFLT-1 ANTIBODIES FOR 
       TREATING OR PREVENTING PREGNANCY-RELATED HYPERTENSIVE DISORDERS

<130>  163173.46376

<140>  US 62/947,821
<141>  2019-12-13

<160>  28    

<170>  PatentIn version 3.5

<210>  1
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1H of AG10B

<400>  1

Gly Tyr Thr Phe Thr Asp Tyr Val Ile Ser 
1               5                   10  


<210>  2
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2H of AG10B

<400>  2

Trp Ile Gly Glu Ile Tyr Pro Gly Ser Gly Ser Ile Tyr Tyr Asn Glu 
1               5                   10                  15      


Lys Phe Lys Gly 
            20  


<210>  3
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3H of AG10B

<400>  3

Gly His Tyr Tyr Gly Tyr Phe Asp Tyr 
1               5                   


<210>  4
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1L of AG10B

<400>  4

Lys Ala Ser Gln Asp Val Thr Ile Thr Val Ala Trp Tyr 
1               5                   10              


<210>  5
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2L of AG10B

<400>  5

Leu Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Thr 
1               5                   10      


<210>  6
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3L of AG10B

<400>  6

Gln Gln His Tyr Thr Thr Pro Trp Thr 
1               5                   


<210>  7
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1H of cENG10

<400>  7

Gly Tyr Thr Ile Thr Glu His Thr Leu His 
1               5                   10  


<210>  8
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2H of cENG10

<400>  8

Gly Ile Asn Phe Asp Asn Gly Gly Thr Thr Tyr Arg Gln Lys Phe Lys 
1               5                   10                  15      


Asp 
    


<210>  9
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3H of cENG10

<400>  9

Arg Ala Tyr Tyr Tyr Gly Ser Ala Phe Asp Tyr 
1               5                   10      


<210>  10
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1L of cENG10

<400>  10

Arg Ala Ser Ser Ser Val Asn Tyr Val Tyr 
1               5                   10  


<210>  11
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2L of cENG10

<400>  11

Tyr Thr Ser Asn Leu Ala Pro 
1               5           


<210>  12
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3L of cENG10

<400>  12

Gln Gln Phe Ile Ser Phe Pro Tyr Thr 
1               5                   


<210>  13
<211>  354
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Nucleotide sequence of chimeric anti-sFlt-1 antibody AG10B 
       variable domain of heavy chain (VH) (without leader sequence)

<400>  13
caggttcagc tgcagcagtc tggacctgag ctggtgaagc ctggggcttc agtgaagatg       60

tcctgcaagg cttctggata cacattcact gactatgtta taagttgggt gaaacagaga      120

actggacagg gccttgagtg gattggagag atttatcctg gaagtggtag tatttactac      180

aatgagaagt tcaagggcaa ggccacactg actgcagaca catcctccaa cacagcctac      240

atgcagctca gcagcctgac atttgaggac tctgcggtca ttttctgtgc aagagggcat      300

tattacggtt actttgacta ctggggccaa ggcaccactc tcacagtctc ctca            354


<210>  14
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Amino acid sequence of chimeric anti-sFlt-1 antibody AG10B 
       variable domain of heavy chain (VH) (without leader sequence)

<400>  14

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Val Ile Ser Trp Val Lys Gln Arg Thr Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Tyr Pro Gly Ser Gly Ser Ile Tyr Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Phe Glu Asp Ser Ala Val Ile Phe Cys 
                85                  90                  95      


Ala Arg Gly His Tyr Tyr Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Thr Leu Thr Val Ser Ser 
        115             


<210>  15
<211>  321
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Nucleotide sequence of chimeric anti-sFlt-1 antibody AG10B 
       variable domain of light chain (VL) (without leader sequence)

<400>  15
gacattgtga tgacccagtc tcacaaattc atgtccacat cagtaggaga cagggtcagc       60

atcacctgca aggccagtca ggatgtgact attactgtag cctggtatca acagaaacca      120

ggacaatctc ctaaacttct gatttactcg gcatcctacc ggtacactgg agtccctgat      180

cgcttcactg gcagtggatc tgggacggat ttcactttca ccatcagcag tgtgcaggct      240

gaagacctgg cagtttatta ctgtcagcaa cattatacta ctccgtggac gttcggtgga      300

ggcaccaagc tggaaatcaa a                                                321


<210>  16
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Amino acid sequence of chimeric anti-sFlt-1 antibody AG10B 
       variable domain of light chain (VL) (without leader sequence)

<400>  16

Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Thr Ile Thr 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala 
65                  70                  75                  80  


Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  17
<211>  1401
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Nucleotide sequence of chimeric anti-sFlt-1 antibody AGB10 heavy 
       chain

<400>  17
atgatgtcct ttgtctctct gctcctggta ggcatcctat tccatgccac ccaggcccag       60

gttcagctgc agcagtctgg acctgagctg gtgaagcctg gggcttcagt gaagatgtcc      120

tgcaaggctt ctggatacac attcactgac tatgttataa gttgggtgaa acagagaact      180

ggacagggcc ttgagtggat tggagagatt tatcctggaa gtggtagtat ttactacaat      240

gagaagttca agggcaaggc cacactgact gcagacacat cctccaacac agcctacatg      300

cagctcagca gcctgacatt tgaggactct gcggtcattt tctgtgcaag agggcattat      360

tacggttact ttgactactg gggccaaggc accactctca cagtctcctc agctagcacc      420

aagggcccat cggtcttccc cctggcaccc tcctccaaga gcacctctgg gggcacagcg      480

gccctgggct gcctggtcaa ggactacttc cccgaaccgg tgacggtgtc gtggaactca      540

ggcgccctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcctc aggactctac      600

tccctcagca gcgtggtgac cgtgccctcc agcagcttgg gcacccagac ctacatctgc      660

aacgtgaatc acaagcccag caacaccaag gtggacaaga gagttgagcc caaatcttgt      720

gacaaaactc acacatgccc accgtgccca gcacctgaac tcctgggggg accgtcagtc      780

ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca      840

tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtatgtggac      900

ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacca aagcacgtac      960

cgtgtggtca gcgtcctcac cgtcctgcac caagactggc tgaatggcaa ggagtacaag     1020

tgcaaggtct ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa     1080

gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggagga gatgaccaag     1140

aaccaagtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag     1200

tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc     1260

gacggctcct tcttcctcta ttccaagctc accgtggaca agagcaggtg gcagcagggg     1320

aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc     1380

ctctccctgt ctccgggctg a                                               1401


<210>  18
<211>  360
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Amino acid sequence of chimeric anti-sFlt-1 antibody AGB10 heavy 
       chain

<400>  18

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Val Ile Ser Trp Val Lys Gln Arg Thr Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Tyr Pro Gly Ser Gly Ser Ile Tyr Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Phe Glu Asp Ser Ala Val Ile Phe Cys 
                85                  90                  95      


Ala Arg Gly His Tyr Tyr Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Thr Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 
        115                 120                 125             


Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 
    130                 135                 140                 


Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 
145                 150                 155                 160 


Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 
                165                 170                 175     


Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 
            180                 185                 190         


Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 
        195                 200                 205             


Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr 
    210                 215                 220                 


His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 
225                 230                 235                 240 


Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 
                245                 250                 255     


Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 
            260                 265                 270         


Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 
        275                 280                 285             


Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gln Ser Thr Tyr Arg Val Val 
    290                 295                 300                 


Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 
305                 310                 315                 320 


Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 
                325                 330                 335     


Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 
            340                 345                 350         


Pro Pro Ser Arg Glu Glu Met Thr 
        355                 360 


<210>  19
<211>  702
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Nucleotide sequence of chimeric anti-sFlt-1 antibody AGB10 light 
       chain

<400>  19
atgatgtcct ttgtctctct gctcctggta ggcatcctat tccatgccac ccaggccgac       60

attgtgatga cccagtctca caaattcatg tccacatcag taggagacag ggtcagcatc      120

acctgcaagg ccagtcagga tgtgactatt actgtagcct ggtatcaaca gaaaccagga      180

caatctccta aacttctgat ttactcggca tcctaccggt acactggagt ccctgatcgc      240

ttcactggca gtggatctgg gacggatttc actttcacca tcagcagtgt gcaggctgaa      300

gacctggcag tttattactg tcagcaacat tatactactc cgtggacgtt cggtggaggc      360

accaagctgg aaatcaaacg gactgtggct gcaccatctg tcttcatctt cccgccatct      420

gatgagcagt tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa cttctatccc      480

agagaggcca aagtacagtg gaaggtggat aacgccctcc aatcgggtaa ctcccaggag      540

agtgtcacag agcaggacag caaggacagc acctacagcc tcagcagcac cctgacgctg      600

agcaaagcag actacgagaa acacaaagtc tacgcctgcg aagtcaccca tcagggcctg      660

agctcgcccg tcacaaagag cttcaacagg ggagagtgtt ag                         702


<210>  20
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Amino acid sequence of chimeric anti-sFlt-1 antibody AGB10 light 
       chain

<400>  20

Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Thr Ile Thr 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala 
65                  70                  75                  80  


Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 
            100                 105                 110         


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 
        115                 120                 125             


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 
    130                 135                 140                 


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 
145                 150                 155                 160 


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 
                165                 170                 175     


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 
            180                 185                 190         


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 
        195                 200                 205             


Phe Asn Arg Gly Glu Cys 
    210                 


<210>  21
<211>  360
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Nucleotide sequence of chimeric anti-sEng antibody cENG10 
       variable domain of heavy chain (VH) (without leader sequence)

<400>  21
gaggtccagc tggaacagtc tggacctgaa gtggtgaagc ctgggacttc agtgaagata       60

tcctgcaaga cttctggata cacaatcact gaacacacct tgcactggat aaagcagaac      120

cagggaaaga gccttgagtg gattggtggt attaattttg acaatggtgg tactacctac      180

aggcagaaat tcaaggacaa ggccacattg actgtggaca agtcctccag cacagccttc      240

atggagctcc gcagcctgac ttctgatgat tctgcagtct atttctgcgc aagaagggcc      300

tattactacg gtagtgcctt tgactactgg ggccaaggca ccactctcac agtctcctca      360


<210>  22
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Amino acid sequence of chimeric anti-sEng antibody cENG10 
       variable domain of heavy chain (VH) (without leader sequence)

<400>  22

Glu Val Gln Leu Glu Gln Ser Gly Pro Glu Val Val Lys Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Ile Thr Glu His 
            20                  25                  30          


Thr Leu His Trp Ile Lys Gln Asn Gln Gly Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Gly Ile Asn Phe Asp Asn Gly Gly Thr Thr Tyr Arg Gln Lys Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Phe 
65                  70                  75                  80  


Met Glu Leu Arg Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg Arg Ala Tyr Tyr Tyr Gly Ser Ala Phe Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Thr Leu Thr Val Ser Ser 
        115                 120 


<210>  23
<211>  318
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Nucleotide sequence of chimeric anti-sEng antibody cENG10 
       variable domain of light chain (VL) (without leader sequence)

<400>  23
gaaaatgtgc tcacccagtc tccagcaatc atgtctgcat ctctagggga gaaggtcacc       60

atgacctgca gggccagctc aagtgtgaat tacgtgtact ggtaccagca gaagtcagat      120

gcctccccca aactatggat ttattacact tccaacctgg ctcctggagt cccagctcgc      180

ttcagtggca gtgggtctgg gaactcttat tctctcacaa tcagcagcat ggagggtgaa      240

gatgctgcca cttattactg ccagcagttt attagtttcc catacacgtt cggagggggg      300

accaagctgg aaataaaa                                                    318


<210>  24
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Amino acid sequence of chimeric anti-sEng antibody cENG10 
       variable domain of light chain (VL) (without leader sequence)

<400>  24

Glu Asn Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Asn Tyr Val 
            20                  25                  30          


Tyr Trp Tyr Gln Gln Lys Ser Asp Ala Ser Pro Lys Leu Trp Ile Tyr 
        35                  40                  45              


Tyr Thr Ser Asn Leu Ala Pro Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Asn Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Gly Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Phe Ile Ser Phe Pro Tyr Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105     


<210>  25
<211>  1407
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Nucleotide sequence of chimeric anti-sEng antibody cENG10 heavy 
       chain

<400>  25
atgggatggt catgtatcat cctttttcta gtagcaactg caactggagt acattcagag       60

gtccagctgg aacagtctgg acctgaagtg gtgaagcctg ggacttcagt gaagatatcc      120

tgcaagactt ctggatacac aatcactgaa cacaccttgc actggataaa gcagaaccag      180

ggaaagagcc ttgagtggat tggtggtatt aattttgaca atggtggtac tacctacagg      240

cagaaattca aggacaaggc cacattgact gtggacaagt cctccagcac agccttcatg      300

gagctccgca gcctgacttc tgatgattct gcagtctatt tctgcgcaag aagggcctat      360

tactacggta gtgcctttga ctactggggc caaggcacca ctctcacagt ctcctcagct      420

agcaccaagg gcccatcggt cttccccctg gcaccctcct ccaagagcac ctctgggggc      480

acagcggccc tgggctgcct ggtcaaggac tacttccccg aaccggtgac ggtgtcgtgg      540

aactcaggcg ccctgaccag cggcgtgcac accttcccgg ctgtcctaca gtcctcagga      600

ctctactccc tcagcagcgt ggtgaccgtg ccctccagca gcttgggcac ccagacctac      660

atctgcaacg tgaatcacaa gcccagcaac accaaggtgg acaagagagt tgagcccaaa      720

tcttgtgaca aaactcacac atgcccaccg tgcccagcac ctgaactcct ggggggaccg      780

tcagtcttcc tcttcccccc aaaacccaag gacaccctca tgatctcccg gacccctgag      840

gtcacatgcg tggtggtgga cgtgagccac gaagaccctg aggtcaagtt caactggtat      900

gtggacggcg tggaggtgca taatgccaag acaaagccgc gggaggagca gtaccaaagc      960

acgtaccgtg tggtcagcgt cctcaccgtc ctgcaccaag actggctgaa tggcaaggag     1020

tacaagtgca aggtctccaa caaagccctc ccagccccca tcgagaaaac catctccaaa     1080

gccaaagggc agccccgaga accacaggtg tacaccctgc ccccatcccg ggaggagatg     1140

accaagaacc aagtcagcct gacctgcctg gtcaaaggct tctatcccag cgacatcgcc     1200

gtggagtggg agagcaatgg gcagccggag aacaactaca agaccacgcc tcccgtgctg     1260

gactccgacg gctccttctt cctctattcc aagctcaccg tggacaagag caggtggcag     1320

caggggaacg tcttctcatg ctccgtgatg catgaggctc tgcacaacca ctacacgcag     1380

aagagcctct ccctgtctcc gggctga                                         1407


<210>  26
<211>  449
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Amino acid sequence of chimeric anti-sEng antibody cENG10 heavy 
       chain

<400>  26

Glu Val Gln Leu Glu Gln Ser Gly Pro Glu Val Val Lys Pro Gly Thr 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Ile Thr Glu His 
            20                  25                  30          


Thr Leu His Trp Ile Lys Gln Asn Gln Gly Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Gly Ile Asn Phe Asp Asn Gly Gly Thr Thr Tyr Arg Gln Lys Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Phe 
65                  70                  75                  80  


Met Glu Leu Arg Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg Arg Ala Tyr Tyr Tyr Gly Ser Ala Phe Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Thr Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 
        115                 120                 125             


Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 
    130                 135                 140                 


Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 
145                 150                 155                 160 


Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 
                165                 170                 175     


Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 
            180                 185                 190         


Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 
        195                 200                 205             


Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 
    210                 215                 220                 


Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 
225                 230                 235                 240 


Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 
                245                 250                 255     


Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 
            260                 265                 270         


Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 
        275                 280                 285             


Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gln Ser Thr Tyr Arg 
    290                 295                 300                 


Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 
305                 310                 315                 320 


Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 
                325                 330                 335     


Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 
            340                 345                 350         


Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 
        355                 360                 365             


Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 
    370                 375                 380                 


Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 
385                 390                 395                 400 


Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 
                405                 410                 415     


Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 
            420                 425                 430         


Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 
        435                 440                 445             


Gly 
    


<210>  27
<211>  699
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Nucleotide sequence of chimeric anti-sEng antibody cENG10 light 
       chain

<400>  27
atgggatggt catgtatcat cctttttcta gtagcaactg caactggagt acattcagaa       60

aatgtgctca cccagtctcc agcaatcatg tctgcatctc taggggagaa ggtcaccatg      120

acctgcaggg ccagctcaag tgtgaattac gtgtactggt accagcagaa gtcagatgcc      180

tcccccaaac tatggattta ttacacttcc aacctggctc ctggagtccc agctcgcttc      240

agtggcagtg ggtctgggaa ctcttattct ctcacaatca gcagcatgga gggtgaagat      300

gctgccactt attactgcca gcagtttatt agtttcccat acacgttcgg aggggggacc      360

aagctggaaa taaaacggac tgtggctgca ccatctgtct tcatcttccc gccatctgat      420

gagcagttga aatctggaac tgcctctgtt gtgtgcctgc tgaataactt ctatcccaga      480

gaggccaaag tacagtggaa ggtggataac gccctccaat cgggtaactc ccaggagagt      540

gtcacagagc aggacagcaa ggacagcacc tacagcctca gcagcaccct gacgctgagc      600

aaagcagact acgagaaaca caaagtctac gcctgcgaag tcacccatca gggcctgagc      660

tcgcccgtca caaagagctt caacagggga gagtgttag                             699


<210>  28
<211>  213
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Amino acid sequence of chimeric anti-sEng antibody cENG10 light 
       chain

<400>  28

Glu Asn Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Asn Tyr Val 
            20                  25                  30          


Tyr Trp Tyr Gln Gln Lys Ser Asp Ala Ser Pro Lys Leu Trp Ile Tyr 
        35                  40                  45              


Tyr Thr Ser Asn Leu Ala Pro Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Asn Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Gly Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Phe Ile Ser Phe Pro Tyr Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro 
            100                 105                 110         


Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr 
        115                 120                 125             


Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys 
    130                 135                 140                 


Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu 
145                 150                 155                 160 


Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 
                165                 170                 175     


Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala 
            180                 185                 190         


Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe 
        195                 200                 205             


Asn Arg Gly Glu Cys 
    210             


